ONCOREF™ Molecular Reference Standards: Application of CRISPR/Cas9 to the Generation of Footprint-Free Isogenic Cell Lines and Nucleic Acid Reference Materials Advancing Genome Engineering Andrew Hilmer, Ph.D. Product Manager MAPK Mutation Series October 4, 2016
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
ONCOREF™ Molecular Reference Standards: Application of CRISPR/Cas9 to the Generation of Footprint-Free
Isogenic Cell Lines and Nucleic Acid Reference Materials
Advancing Genome Engineering
Andrew Hilmer, Ph.D.Product Manager
MAPK Mutation SeriesOctober 4, 2016
2
• Background
• Isogenic Cell Line Generation
• Application to Molecular Reference Standards
• Other Custom Services at Applied StemCell
Outline
3
• In 2016, in the US1:
– 1.7 M new cases of cancer diagnosed
– 600,000 people will die from the disease (~1 person/minute)
• 3-35% of premature deaths could be avoided with better screening methods2
Why Did We Develop this Product Series
Goal: Develop a toolset that can be used for enabling research into better diagnostics and treatment
1. Am Canc Soc. “Cancer Facts and Figures 2016”2. www.cancer.gov
4
• 51 Cell Lines Engineered Using CRISPR/Cas9
– MAPK mutations from COSMIC
– 32 Mutations in EGFR (RKO)
– 12 Mutations in KRAS (HCT-116)
– 7 Mutations in BRAF (RKO)
• Isogenic Positive and Negative Controls
• Mutations are Homozygous and Footprint-Free
• Available in a Number of Formats:
– Genomic DNA
– FFPE Slides, and Scrolls
– Cell Lines
Introduction to ONCOREF™ Product Series
Research Use Only
5
Background on MAPK Pathway
• Pathway involved in:
– Cell proliferation, cell death, differentiation, migration, and invasion
• Frequently mutated in cancer:
– KRAS mutations in >90% of pancreatic cancers1
– BRAF mutations in ~50% of melanomas2
– 20-50% of NSCLC are EGFR mutant3
1. Eser, S et al. Brit. J. Cancer. 111, p817-822 (2014)2. Ascierto, PA et al. J. Transl. Med., 10:85, (2012)3. Midha, A et al. Am. J. Canc. Res, 5, p2892-2911 (2015)
6
MAPK Cell Line Series:Cas9-Mediated Genome Engineering
gRNA directs Cas9 to target site
DSB
No RepairTemplate Available
RepairTemplate Available
NHEJ HDR
Error-ProneOften Results in Indel Formation
PreciseUses the Template You Provide
1 2
7
MAPK Cell Line Series:Cas9 for Footprint-Free Genome Editing
Footprint-FreeFootprint
8
MAPK Cell Line Series:Cell Line Engineering Workflow
Clonally Homogeneous Genetically Validated
Homozygous Modification
9
Single Cell Cloning
Clonal Expansion
Cas9 Transfection
Example 1: Point Mutation Example 2: Small Insertion Example 3: Deletionc.2310_2311insGGTp.D770_N771insG
c.2303G>Tp.S768I
c.2239_2256del18p.L747_S752del
MAPK Cell Line Series:Engineering Clinically Relevant Mutations
10
*
*****
************
*******
***
*
*
= Exclusive to ASC *
12 KRAS Mutations
7 BRAF Mutations
32 EGFR Mutations
**
Research Use Only
MAPK Cell Line Series:Full Mutation Panel
11
MAPK Cell Line Series Highlights:Largest Panel of EGFR Exon 19 Mutations
• 22 Deletion Mutations
• In-frame mutations that occur within kinase domain
• 21 mutations are unique to ASC
c. 2238_2252>GCAp. L747_T751>QCOSM12419
COSM12422c. 2238_2248>GCp. L747_A750>P
Exon 19 Mutation Panel
Cheng, L, et al. Modern Pathology, 25, p 347-369 (2012)
Research Use Only
12
Assay Development
Optimize sample processing protocols
Establish limit of detection (LOD)
Identify and validate optimal reagents
Monitor the impact of workflow changes on results
Quality Control and Assay Reproducibility
Accurately evaluate batch-to-batch variability
Easily transfer workflows across labs or institutions
MAPK FFPE Cell Line Standards:Consistent Source of Bio-Relevant Specimens
Research Use Only
13
Tumor Xenografts
Plasmids
Amplicons
Genomic DNA
FFPE Cell Blocks
Bio-RelevantHighly-Reproducible
Yes No
Yes
Yes
Yes
No
No Yes
Yes
Yes
Research Use Only
MAPK FFPE Cell Line Standards:Consistent Source of Bio-Relevant Specimens